Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BridgeBio Pharma ( (BBIO) ) has provided an announcement.
On January 12, 2026, BridgeBio Pharma used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to highlight strong early commercial traction for Attruby, its ATTR-CM therapy, reporting preliminary unaudited 2025 net product revenue of $362.4 million, supported by 6,629 unique patient prescriptions from 1,632 prescribers, and to announce a new TTR amyloid-depleting antibody program expected to progress to the clinic between 2027 and 2028. The company also reported pivotal data and regulatory momentum across its late-stage pipeline, including a positive interim Phase 3 FORTIFY readout in LGMD2I/R9 that prompted FDA guidance to pursue a traditional full approval pathway and an NDA filing planned for the first half of 2026, an NDA timeline in the same period for encaleret in ADH1 amid rapid growth in diagnosed patients, a planned Phase 3 trial of encaleret in chronic hypoparathyroidism starting in summer 2026, and advancing registrational studies of infigratinib in pediatric achondroplasia and hypochondroplasia, all underpinned by approximately $587.5 million in cash and marketable securities at year-end 2025 to support continued Attruby growth and potential global launches of up to three additional medicines.
The most recent analyst rating on (BBIO) stock is a Buy with a $98.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.
Spark’s Take on BBIO Stock
According to Spark, TipRanks’ AI Analyst, BBIO is a Neutral.
BridgeBio Pharma’s overall stock score is driven by strong technical momentum and positive earnings call highlights, including successful Phase III trials and revenue growth. However, financial performance and valuation concerns, such as negative profitability and high leverage, weigh down the score.
To see Spark’s full report on BBIO stock, click here.
More about BridgeBio Pharma
BridgeBio Pharma, Inc., listed on Nasdaq as BBIO, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative medicines for patients with genetic diseases. Founded in 2015 and based in Palo Alto, California, the company runs a decentralized pipeline that spans early-stage research through late-stage clinical programs, with its flagship commercial product Attruby (acoramidis), a transthyretin stabilizer for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Average Trading Volume: 2,245,360
Technical Sentiment Signal: Buy
Current Market Cap: $14.23B
For detailed information about BBIO stock, go to TipRanks’ Stock Analysis page.